Sept 16 (Reuters) - Bionomics Ltd BNO.AX :
* Reports positive data from phase 1 multiple ascending dose trial of bnc210
for anxiety and depression
* Says all primary and secondary endpoints met, no adverse effects on cognition
or emotional stability and no abuse potential indicated
* Says ongoing phase 2 trial in patients with generalized anxiety disorder
anticipated to report data in q3,2016
* Source text for Eikon ID:nPn4bsw12
* Further company coverage BNO.AX